Combination therapy is a new standard for treatment of pulmonary arterial hypertension

• Published in: Terapevtic̆eskii arhiv Vol. 90; no. 3; pp. 72 - 80
• Main Authors: Avdeev, S N, TsarEva, N A, Gaisin, I R
• Format: Journal Article
• Language: English; Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 19-04-2018
• Subjects: Antihypertensive Agents; combination therapy; Combined Modality Therapy; Humans; Hypertension, Pulmonary - therapy; pulmonary arterial hypertension; pulmonary hypertension; Quality of Life; specific therapy; combination therapy; specific therapy; pulmonary arterial hypertension; pulmonary hypertension
• ISSN: 0040-3660; 2309-5342
• DOI: 10.26442/terarkh201890372-80

At present, compelling evidence has been obtained that combined therapy of pulmonary arterial hypertension (PAH) with specific drugs can significantly slow progression of PAH. Therefore, in current guidelines combination therapy is already considered as standard treatment for a significant proportion of patients with moderately severe and severe forms of PAH. However, the quality of life and long-term prognosis of patients receiving combination therapy, should be the object of further research. The future research is absolutely necessary to identify the most optimal strategy of treatment of patients with PAH, such as initial combination therapy or rapid sequential combination therapy, double or triple combinations as well as exploring new signaling pathways PAH, which can become targets for new specific drugs PAH.